An Open-Label Single-Dose Crossover Pharmacokinetic Study to Compare CTP-543 to Jakafi® in Healthy Volunteers

Trial Profile

An Open-Label Single-Dose Crossover Pharmacokinetic Study to Compare CTP-543 to Jakafi® in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Ruxolitinib deuterated (Primary) ; Ruxolitinib
  • Indications Alopecia areata
  • Focus Pharmacokinetics
  • Sponsors Concert Pharmaceuticals
  • Most Recent Events

    • 27 Mar 2017 Status changed from recruiting to completed.
    • 15 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top